Hadlima Solution
Product Images NDC 50090-6705

Product Visual Gallery

This gallery contains 68 technical images submitted to the FDA as part of the official labeling for Hadlima (NDC 50090-6705). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A line graph comparing the percentage of ACZ120 responders over time in weeks between two groups: one receiving 40 mg every other week and a placebo group. The x-axis represents time in weeks, and the y-axis represents the percent of responders, showing a higher response rate in the 40 mg group throughout the study period.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting the percentage of ASA 20 response over time in weeks. Two groups are compared: placebo (N=107) shown as a dashed line, and Adalimumab (N=208) shown as a solid line, with Adalimumab demonstrating a higher response rate throughout the 24-week period.*

FDA Label Image

Samsung Logo (Image 03)

FDA Label Image

Organon Logo (Image 04)

Packaging label segment showing manufacturing information for HADLIMA (adalimumab-bwwd) solution 40 mg/0.8 mL. It states that the product is manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ 07302, USA.*

FDA Label Image

Samsung Logo (Image 05)

FDA Label Image

Organon Logo (Image 06)

FDA Label Image

Figure A (Prefilled Syringe)

An instructional illustration labeled Figure A showing the parts of a syringe used for subcutaneous injection. The diagram identifies the needle cap, the syringe body with a window to view contents, the flange for finger placement, and the plunger for administering the injection.*

FDA Label Image

Refrigerator (Image 08)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection. The packaging includes the 0.8 mL prefilled syringe and product information. Labeler is A-S Medication Solutions. The product is a human prescription drug containing adalimumab-bwwd.*

FDA Label Image

Light (Image 09)

Label for HADLIMA 40 mg/0.8 mL solution, a subcutaneous injection of adalimumab-bwwd. The label includes dosing instructions for a prefilled pen with specified injection times. Labeler is A-S Medication Solutions.*

FDA Label Image

Caution (Image 10)

HADLIMA 40 mg/0.8 mL subcutaneous solution, human prescription drug by A-S Medication Solutions. The image shows a single-use vial with label including the proprietary name, dosage strength, and directions for use. The vial cap is purple and the label predominantly white with purple accents.*

FDA Label Image

Container (Image 11)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection in a prefilled syringe is shown in its packaging. The cardboard box features the product name, dosage strength, and manufacturer A-S Medication Solutions. A syringe with the solution is also visible alongside the carton, indicating the product's form and administration route.*

FDA Label Image

Figure B (Prefilled Syringe)

An instructional illustration labeled Figure B showing a human hand wearing a pink watch with the watch face displaying the time, positioned next to a syringe partially filled with medication. The image appears to depict timing or preparation related to subcutaneous injection.*

FDA Label Image

Figure C (Prefilled Syringe)

An instructional illustration showing a prefilled syringe for a subcutaneous solution, accompanied by an alcohol swab packet, a red sharps container, and several cotton balls or gauze pads (not included in the carton). This image outlines essential components for proper injection preparation and disposal.*

FDA Label Image

Figure D (Prefilled Syringe)

Illustration showing a hand holding a syringe with HADLIMA solution, emphasizing three pre-injection checks: ensuring the solution is clear, confirming no particles are present, and verifying the expiration date on the vial or syringe.*

FDA Label Image

Figure E (Prefilled Syringe)

An instructional illustration showing suitable subcutaneous injection sites on the front of a male torso, highlighting the abdomen and front of the thighs. The image also depicts an alcohol swab packet alongside the instruction to "Clean your skin," emphasizing skin preparation before injection.*

FDA Label Image

Figure F (Prefilled Syringe)

An instructional illustration showing two hands assembling a prefilled syringe by attaching a needle. The image highlights the needle cap being aligned and pushed onto the syringe tip, indicated by an arrow.*

FDA Label Image

Figure G (Prefilled Syringe)

An instructional illustration showing proper technique for subcutaneous injection. The image depicts a hand holding a syringe at a 45-degree angle to the skin of the opposite hand, indicating the recommended needle insertion angle for administration.*

FDA Label Image

Figure H (Prefilled Syringe)

An instructional illustration showing hands administering a subcutaneous injection using a prefilled syringe. One hand holds the syringe with the thumb pushing the plunger, directed at the skin of the opposite hand's finger area. The blue arrow indicates the direction to press the plunger.*

FDA Label Image

Figure I (Prefilled Syringe)

An instructional illustration showing a hand holding a syringe with a needle retracted, near a sharps container. Text advises confirming the dose by checking the needle is retracted and no medicine is leaking, though a small drop is acceptable.*

FDA Label Image

Samsung Logo (Image 20)

FDA Label Image

Organon Logo (Image 21)

The image shows a product label for HADLIMA, adalimumab-bwwd solution 40 mg/0.8 mL for subcutaneous use. It states the product is manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ, USA. The labeler is A-S Medication Solutions.*

FDA Label Image

Figure A (Autoinjector)

Illustration labeled "Figure A" showing a prefilled syringe for HADLIMA (adalimumab-bwwd) 40 mg/0.8 mL. The diagram identifies the needle cap at the syringe tip, the base below the needle cap, a medicine window in the barrel allowing visibility of the medication, and a medicine label near the syringe plunger end.*

FDA Label Image

Refrigerator (Image 23)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection vial label by A-S Medication Solutions. The label shows the product name, strength, dosage form, and route of administration. The vial is clear with a blue cap and contains a colorless liquid.*

FDA Label Image

Light (Image 24)

HADLIMA 40 mg/.8 mL solution for subcutaneous injection packaged in a carton. The label indicates it is a human prescription drug containing the active ingredient adalimumab-bwwd. The product is labeled by A-S Medication Solutions, with NDC 50090-6705.*

FDA Label Image

Caution (Image 25)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection vial label. The label includes the proprietary name, generic name adalimumab-bwwd, and indicates it is a human prescription drug. The labeler is A-S Medication Solutions. The vial is amber-colored with a gray cap and has clear printed text and barcode.*

FDA Label Image

Container (Image 26)

HADLIMA 40 mg/0.8 mL subcutaneous injection solution carton and vial label by A-S Medication Solutions. The labels show the proprietary and generic name adalimumab-bwwd, with dosage strength and route, including barcodes and storage information on the vial.*

FDA Label Image

Figure B (Autoinjector)

An illustration labeled Figure B shows a left wrist wearing a pink watch indicating the time elapsed, alongside a subcutaneous injection device with a visible dose indicator. This image likely demonstrates timing or use instructions related to the injection process for HADLIMA (adalimumab-bwwd) solution.*

FDA Label Image

Figure C (Autoinjector)

An instructional illustration showing a HADLIMA autoinjector pen along with an alcohol swab packet labeled 70% isopropyl, a red sharps container, and cotton balls or gauze. The illustration notes that the alcohol swab, sharps container, and cotton ball or gauze are not included in the carton.*

FDA Label Image

Figure D (Autoinjector)

Illustration showing a hand holding a HADLIMA 40 mg/.8 mL prefilled syringe for subcutaneous use, highlighting visual checks before injection. It emphasizes inspecting the syringe solution for clarity and absence of particles, and verifying the expiration date on the syringe label.*

FDA Label Image

Figure E (Autoinjector)

An instructional illustration showing recommended injection sites on the human body for subcutaneous administration. The marked sites include the abdomen and upper thigh. The image also advises cleaning the skin prior to injection and includes a depiction of an alcohol swab packet labeled '70% Isopropyl'.*

FDA Label Image

Figure F (Autoinjector)

An instructional illustration showing hands preparing a syringe for use. The left hand holds a vial with a cap to be removed by pulling upward, while the right hand holds the syringe ready to access the vial. The image is labeled Figure F and uses arrows to indicate the removal direction of the vial cap.*

FDA Label Image

Figure G (Autoinjector)

An instructional illustration showing a hand pressing down on a syringe, indicated by a blue downward arrow and the word 'Click' in blue with a red checkmark, likely demonstrating the activation or injection step for a subcutaneous solution.*

FDA Label Image

Figure H (Autoinjector)

Illustration showing a hand gripping an object with an inset zoom highlighting a yellow line feature. A label near the hand reads 'Click' indicating an action to perform. This instructional diagram is from the HADLIMA adalimumab-bwwd subcutaneous solution product labeling.*

FDA Label Image

Figure I (Autoinjector)

An instructional illustration showing a hand holding a subcutaneous injection device with a medicine window colored yellow, indicating a correct dose. A sharps container is nearby, emphasizing safe disposal of used needles.*

FDA Label Image

Samsung Logo (Image 35)

FDA Label Image

Organon Logo (Image 36)

Packaging label showing manufacturing information for HADLIMA (adalimumab-bwwd) 40 mg/0.8 mL solution for subcutaneous injection. The product is manufactured for Organon LLC, a subsidiary of ORGANON & Co., located in Jersey City, NJ, USA.*

FDA Label Image

Figure A (Prefilled Syringe)

Illustration labeled Figure A showing parts of a syringe including the needle cap, body with window, flange, and plunger. The syringe is depicted in a side view, highlighting each component for identification purposes.*

FDA Label Image

Refrigerator (Image 38)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection packaging label. The label includes the proprietary name HADLIMA and indicates the product contains adalimumab-bwwd. The labeler is A-S Medication Solutions. The packaging is primarily white with blue text and design elements.*

FDA Label Image

Light (Image 39)

Packaging label of HADLIMA 40 mg/0.8 mL solution for subcutaneous injection. The label features the proprietary name HADLIMA and includes branding elements with blue and orange colors. The product is labeled as a human prescription drug by A-S Medication Solutions.*

FDA Label Image

Caution (Image 40)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection carton. The packaging features the brand name HADLIMA prominently with the active ingredient adalimumab-bwwd indicated. The label shows the dosage strength 40 mg per 0.8 mL and includes the labeler name A-S Medication Solutions. The packaging is primarily white with some blue and black text and graphics.*

FDA Label Image

Container (Image 41)

HADLIMA solution for subcutaneous injection, 40 mg/0.8 mL, in a single-dose prefilled syringe. The packaging displays the proprietary name HADLIMA and the labeler A-S Medication Solutions. The syringe is clear with a white plunger and a cap over the needle end.*

FDA Label Image

Figure B (Prefilled Syringe)

An instructional illustration showing a wrist with a pink watch beside a subcutaneous injection pen or syringe, likely demonstrating timing or administration technique associated with the injection process.*

FDA Label Image

Figure C (Prefilled Syringe)

An instructional illustration labeled Figure C displaying a prefilled syringe along with images of an alcohol swab, a sharp container, and a cotton ball or gauze. Text indicates these additional items are not included in the carton.*

FDA Label Image

Figure D (Prefilled Syringe)

An instructional illustration labeled Figure D showing a hand holding a syringe with solution. The image highlights a checklist to verify before use: ensure the solution is clear, contains no particles, and check the expiration date on the syringe.*

FDA Label Image

Figure E (Prefilled Syringe)

An instructional illustration showing a human figure with recommended injection sites on the abdomen and thighs for subcutaneous administration. The image also includes a depiction of an alcohol swab with the instruction to clean the skin before injection, emphasizing proper preparation.*

FDA Label Image

Figure F (Prefilled Syringe)

Illustration depicting hands preparing a syringe by removing the cap, shown with an arrow indicating the direction to pull the cap off. The image is instructional, likely related to administering a subcutaneous solution such as HADLIMA (adalimumab-bwwd).*

FDA Label Image

Figure G (Prefilled Syringe)

An instructional illustration showing a hand holding a syringe injecting at a 45-degree angle into the skin of another hand, demonstrating proper subcutaneous injection technique.*

FDA Label Image

Figure H (Prefilled Syringe)

An instructional illustration showing a person preparing to inject a subcutaneous solution using a syringe. One hand holds the syringe at the plunger end, with a blue arrow indicating the thumb position, while the other hand is positioned to receive the injection in the skin, likely the forearm.*

FDA Label Image

Figure I (Prefilled Syringe)

An instructional illustration showing a hand holding a syringe near a sharps container. The text advises to dispose of the syringe if the needle is retracted and no medicine has leaked out, noting that a small drop is acceptable.*

FDA Label Image

Samsung Logo (Image 50)

FDA Label Image

Organon Logo (Image 51)

FDA Label Image

Figure A (Autoinjector)

An instructional diagram labeled Figure A illustrating the components of a prefilled syringe. It points out the needle cap, base, medicine window, and medicine label areas on the syringe barrel, likely for the HADLIMA 40 mg/0.8 mL solution for subcutaneous use.*

FDA Label Image

Refrigerator (Image 53)

HADLIMA 40 mg/0.8 mL subcutaneous solution packaging label. The label shows the product name HADLIMA and the active ingredient adalimumab-bwwd. It also includes dosage information and is labeled by A-S Medication Solutions. The label design includes graphical elements with blue accents.*

FDA Label Image

Light (Image 54)

HADLIMA 40 mg/.8 mL solution for subcutaneous injection vial label. The label displays the brand name HADLIMA prominently with active ingredient adalimumab-bwwd noted. The label includes a lot number, expiration date, and manufacturer information for A-S Medication Solutions. The vial contains 0.8 mL of solution.*

FDA Label Image

Caution (Image 55)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection packaging label by A-S Medication Solutions. The image shows a white box with product and dosage details, including the proprietary name, strength, dosage form, and labeler information.*

FDA Label Image

Container (Image 56)

HADLIMA 40 mg/.8mL solution for subcutaneous injection. The product is labeled as a human prescription drug containing adalimumab-bwwd. The packaging highlights the A-S Medication Solutions labeler and lists the NDC 50090-6705. The image shows the front of the carton with relevant dosage and product information.*

FDA Label Image

Figure B (Autoinjector)

An instructional illustration labeled 'Figure B' showing a wrist with a pink watch indicating time and a blue and gray injection pen device representing a subcutaneous injection process, likely related to HADLIMA administration timing or technique.*

FDA Label Image

Figure C (Autoinjector)

Illustration showing the HADLIMA autoinjector pen for subcutaneous injection of adalimumab-bwwd 40 mg/0.8 mL solution, accompanied by images of an alcohol swab, a sharps container, and cotton balls or gauze as associated supplies (not included in the carton).*

FDA Label Image

Figure D (Autoinjector)

Illustration showing a hand holding a HADLIMA PushTouch 40 mg/.8 mL prefilled syringe. The diagram highlights checking the syringe for clarity and absence of particles, as well as verifying the expiration date on the label before use.*

FDA Label Image

Figure E (Autoinjector)

An instructional illustration showing areas on a person's abdomen and thighs recommended for subcutaneous injection. The image includes a note to clean the skin with an alcohol swab before injection, accompanied by a depiction of a 70% isopropyl alcohol swab packet.*

FDA Label Image

Figure F (Autoinjector)

An instructional illustration labeled Figure F showing two hands preparing a subcutaneous injection device by removing a cap from the injection pen. The right hand holds the pen while the left hand pulls the cap away to expose the injection site.*

FDA Label Image

Figure G (Autoinjector)

An instructional diagram labeled Figure G, showing a hand holding a device vertically to administer a subcutaneous injection. The image includes a blue downward arrow indicating the direction for injecting and the word 'Click' with a checkmark, suggesting activation or confirmation of the injection process.*

FDA Label Image

Figure H (Autoinjector)

An instructional diagram labeled Figure H showing the correct hand positioning for injecting HADLIMA (adalimumab-bwwd) 40 mg/0.8 mL subcutaneous solution. The illustration highlights the injection site on the skin and the view of a window on the device confirming the injection with a "Click" sound.*

FDA Label Image

Figure I (Autoinjector)

Illustration showing a hand holding a syringe for HADLIMA (adalimumab-bwwd) solution subcutaneous injection, demonstrating how to confirm the correct dose. The diagram highlights a yellow medicine window on the syringe and notes that no medicine leakage should be present, except a small drop is acceptable, with a sharps container labeled in the background.*

FDA Label Image

Samsung Logo (Image 65)

FDA Label Image

Organon Logo (Image 66)

The image shows a labeling detail for HADLIMA (adalimumab-bwwd) showing it is manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ, USA.*

FDA Label Image

Figure 3 (Image 72)

Two line graphs titled 'Study UV I' and 'Study UV II' depict treatment failure rates over 20 months for placebo and Humira (adalimumab). The x-axis is labeled 'Time [Months]' and the y-axis 'Treatment Failure Rate [%]'. Each graph shows separate curves for placebo and Humira, with treatment failure rates increasing over time and numerical patient counts below each time point.*

FDA Label Image

Label Image (Lbl500906705)

The packaging label for HADLIMA (adalimumab-bwwd) 40 mg/0.8 mL solution for subcutaneous injection. The label shows packaging for 2 single-use prefilled syringes, with storage instructions to store refrigerated at 36 to 46°F, along with manufacturer information from A-S Medication Solutions, Libertyville, IL 60048. The NDC number is 50090-6705-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.